Administration of pharmacological agents acting on neurotransmitter system thought to be involved in the pathogenesis of schizophrenia is used in modeling this disorder. Antagonists of glutamatergic NMDA receptors such as MK-801 are used to create behavioral analogs of the positive symptoms of schizophrenia such as hyperlocomotion and pre-pulse inhibition deficits. This model is applicable to both mice and rats.
Yarkov et al., 2010: Effects of MK-801 administration on locomotor activity in WT mice or dopamine receptor D3 knockout mice (D3RKO mice). Animals first receive an injection of saline and thereafter their baseline motor activity in an arena is measured. After 35 min, an injection of saline or MK-801 at 0.12 mg/kg is administrated and effect on locomotion is evaluated. D3RKO mice are more sensitive to the effect of MK-801 to increase locomotor activity. Significant differences are: &- Saline-saline treated WT versus saline-saline treated KO mice group. *- saline-MK-801 treated KO vs. saline-saline treated KO mice. #- saline-MK-801 treated KO vs. saline-saline treated WT group. $- saline-MK-801 treated KO vs. saline-MK-801 treated WT group (significant differences).
Yarkov AV, Der TC, Joyce JN (2009) Locomotor activity induced by mk-801 is enhanced in dopamine d3 receptor knockout mice but suppression by dopamine d3/d2 antagonists does not occur through the dopamine d3 receptor. Eur J Pharmacol 627(1-3):167-172
Lotan A, Lifschytz T, Slonimsky A, Broner EC, Greenbaum L, Abedat S, Fellig Y, Cohen H, Lory O, Goelman G, Lerer B (2013) Neural mechanisms underlying stress resilience in ahi1 knockout mice: relevance to neuropsychiatric disorders. Mol Psychiatry 19(2):243-252